MetLife Investment Management’s Pyxis Oncology PYXS Stock Holding History
Bought
Maintained
Sold
Other funds holding PYXS
P
LCM
PAI
IC
MetLife Investment Management's PYXS Position: Q4 2024 in Review
MetLife Investment Management sold out of Pyxis Oncology (PYXS) in Q4 2024, closing a stake of 18,818 shares — an estimated $69.1K sold.
MetLife Investment Management first reported a position in PYXS in Q2 2024 and held it in 2 quarters. The position peaked at $69.1K in Q3 2024. 99 funds tracked by Wall St. Rank hold PYXS as of Q4 2024.
- MetLife Investment Management reported no remaining Pyxis Oncology position as of Q4 2024 after selling out during the quarter.
- MetLife Investment Management sold 18,818 Pyxis Oncology shares in Q4 2024, an estimated $69.1K.
- MetLife Investment Management first reported a position in Pyxis Oncology in Q2 2024 and held it in 2 quarters.
- MetLife Investment Management's Pyxis Oncology position peaked at $69.1K in Q3 2024.
- 99 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2024.
Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.